WuXi Biologics Opens New Manufacturing Facility In China

WuXi Biologics has launched a commercial-scale biologics perfusion manufacturing facility in Wuxi City, China.

AsianScientist (Sep. 28, 2016) – WuXi Biologics, a open-access biologics research and technology platform company, has opened a new commercial-scale biologics perfusion manufacturing facility in Wuxi City, China.

WuXi Biologics is a wholly-owned subsidiary of WuXi AppTec, a global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company.

In April 2015, WuXi Biologics first announced plans to build a US$150 million commercial biologics manufacturing facility in Wuxi City. The first phase of construction has been completed, and it began operations in September 2016. This facility is among the largest perfusion biologics manufacturing facility implementing disposable bioreactors in Asia.


———

Source: WuXi AppTec; Photo: WuXi Biologics.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist